Every briefing on this terminal is assigned a Rank based on the quality of underlying clinical data. Data integrity is our only priority.
The Gold Standard. Requires replicated hazard ratio data across at least two independent large cohorts (n > 10,000 combined), with all-cause or cause-specific mortality as the primary endpoint. DunedinPACE or epigenetic clock validation, where available, is treated as supporting evidence — not a requirement.
High-confidence intervention. The biological mechanism and direction of benefit are clear. Long-term longitudinal mortality data is either in aggregation phase or proxied through validated surrogate endpoints (e.g. VO₂max, HbA1c, HOMA-IR). A Grade B article should state explicitly which evidence component justifies the rating.
Experimental signal. Human data exists but is limited by sample size, short follow-up, or high confounding. Animal and mechanistic models suggest the pathway is real — but human bioavailability, dose-response, and individual variability are not yet codified at population scale.
Biologically interesting but unvalidated in living subjects. May be included for completeness or future tracking. Never used as a protocol recommendation. If a Grade D article is published, it must carry a visible disclaimer in the article body.
"A hypothesis earns the right to become a protocol only when the data can bear the weight of a human body."
See the grading system applied across every clinical briefing in the archive.
Browse the Research Archive